Search

Clear all

Refine your search

Content type
Territory

20 results found

Article

Robins Kaplan LLP | USA | 10 Oct 2019

NDAs: The Biggest Bang for your IP Buck?

Non-disclosure agreements (NDAs) may be the most powerful tool in your Intellectual Property (IP) portfolio. Often NDAs are some of the first steps

Article

Robins Kaplan LLP | USA | 19 Sep 2019

Amgen Inc. v. Amneal Pharms. LLC

The court denied defendant's motion to enforce its settlement agreement with plaintiff after the at-risk launch and subsequent settlement of another

Article

Robins Kaplan LLP | USA | 16 Sep 2019

Duke Univ. v. Akorn, Inc.

The court granted plaintiffs’ motion to dismiss Defendant’s antitrust and patent misuse counterclaims and related affirmative defenses.

Article

Robins Kaplan LLP | USA | 29 Aug 2019

Allergan Sales, LLC v. Sandoz, Inc

“Wherein” clauses in a method of treatment claim are claim limitations that should be given weight, resulting in the affirmance of a preliminary

Article

Robins Kaplan LLP | USA | 21 Aug 2019

Galderma Labs L.P. v. Teva Pharms. USA, Inc.

The asserted claims of 1 ivermectin formulation are invalid on the basis of anticipation in light of a prior art reference that teaches application

Article

Robins Kaplan LLP | USA | 17 Aug 2019

INO Therapeutics LLC v. Praxair Distribution Inc.

But for a clerical error to be addressed on remand, the Federal Circuit affirms findings of ineligible subject matter and non-infringement.

Article

Robins Kaplan LLP | USA | 15 Aug 2019

Nalpropion Pharms., Inc. v. Actavis Labs. FL, Inc.

The Federal Circuit affirmed the district court's finding that one of the patents was adequately described, but reversed the district court's finding

Article

Robins Kaplan LLP | USA | 14 Aug 2019

Sanofi-Aventis U.S., LLC v. Dr. Reddy’s Labs., Inc.

Plaintiff's disclaimer of claims found invalid by the PTAB mooted any controversy before the appellate court associated with that patent, and a

Article

Robins Kaplan LLP | USA | 13 Aug 2019

Valeant Pharms. N. Am. LLC v. Zydus Pharms. (USA) Inc.

Because plaintiffs failed to show specifically how defendants committed any act of infringement in New Jerseyparticularly by filing an ANDA in West

Article

Robins Kaplan LLP | USA | 6 Aug 2019

Forest Labs., LLC v. Sigmapharm Labs., LLC

The court denies Defendant’s motion for judgment of non-infringement in response to ANDA holder modification of its ANDA specification after trial.

Previous page 1 2